Genetics Generation Advancement Corp. (4160.TWO)
- Previous Close
55.30 - Open
57.00 - Bid 54.80 x --
- Ask 55.00 x --
- Day's Range
54.00 - 57.00 - 52 Week Range
46.90 - 150.87 - Volume
24,845 - Avg. Volume
52,727 - Market Cap (intraday)
1.473B - Beta (5Y Monthly) 0.32
- PE Ratio (TTM)
27.06 - EPS (TTM)
2.04 - Earnings Date --
- Forward Dividend & Yield 0.51 (0.91%)
- Ex-Dividend Date Sep 19, 2024
- 1y Target Est
--
Genetics Generation Advancement Corp. provides genetic testing and informatics services in Taiwan. The company offers testing services, including pre-implantation, prenatal, newborn medical examination, health management, reproductive medicine testing, obstetrics and gynecology testing, and neonatology and pediatrics testing, as well as gastroenterology, hepatology, oncology, and medical research services. It also provides life sciences, materials sciences, research and development management, enterprise quality management, process production operation, and e-submission products. The company was formerly known as Genesis Genetics Asia Corp. and changed its name to Genetics Generation Advancement Corp. in February 2016. Genetics Generation Advancement Corp. was founded in 2008 and is based in Taipei City, Taiwan.
www.gga.asia--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 4160.TWO
View MorePerformance Overview: 4160.TWO
Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4160.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4160.TWO
View MoreValuation Measures
Market Cap
1.48B
Enterprise Value
1.10B
Trailing P/E
27.11
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.24
Price/Book (mrq)
2.67
Enterprise Value/Revenue
1.67
Enterprise Value/EBITDA
12.83
Financial Highlights
Profitability and Income Statement
Profit Margin
8.26%
Return on Assets (ttm)
4.69%
Return on Equity (ttm)
11.15%
Revenue (ttm)
661.85M
Net Income Avi to Common (ttm)
54.7M
Diluted EPS (ttm)
2.04
Balance Sheet and Cash Flow
Total Cash (mrq)
412.9M
Total Debt/Equity (mrq)
7.29%
Levered Free Cash Flow (ttm)
41.37M